SUWA, Japan–(BUSINESS WIRE)– Saint-Gobain Life Sciences heeft vandaag de toevoeging aangekondigd van hun productiefaciliteit in Suwa, Japan voor de productie van C-Flex® TPE-slangen voor gebruik in bioprocessing. De capaciteitsuitbreiding in Suwa maakt deel uit van het doorlopende investeringsplan van Saint-Gobain Life Sciences om de productiecapaciteit voor haar producten en diensten die in de bioverwerkingsector worden gebruikt, wereldwijd uit te breiden.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20220615005135/en/

“De uitbreiding van de Suwa-site verbetert ons wereldwijde productienetwerk verder, met een specifieke nadruk op het ondersteunen van de beschikbaarheid van onze C-Flex® TPE-slangen in Azië”, zegt Benjamin Le Quéré, algemeen directeur van de business unit Bioprocess Solutions bij Saint-Gobain Life Sciences. “Met de voltooiing van Suwa’s capaciteit, zullen we C-Flex®-productiecapaciteit hebben in vijf afzonderlijke faciliteiten in vier landen. Dit is een unieke mogelijkheid in TPE-slangen voor bioprocessing en het ondersteunt onze missie om leveringszekerheid te bieden.”

Saint-Gobain Bioprocess Solutions Business Announces C-Flex® Production Capability in Suwa, Japan

SUWA, Japan–(BUSINESS WIRE)– Saint-Gobain Life Sciences today announced the addition of their Suwa, Japan manufacturing facility for the production of C-Flex^® TPE tubing for use in bioprocessing. The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005135/en/

Saint-Gobain Life Sciences C-Flex® tubing extrusion in facility clean room. (Photo: Business Wire)

“The Suwa site expansion further enhances our global manufacturing network, with a specific emphasis on supporting availability of our C-Flex^® TPE tubing in Asia,” said Benjamin Le Quéré, Bioprocess Solutions business unit General Manager at Saint-Gobain Life Sciences. “With the completion of Suwa’s capability, we will have C-Flex^® production capacity in five separate facilities in four countries. This is a unique capability in TPE tubing for bioprocessing and it supports our mission to provide security of supply.”

“We have been making substantial progress on improving C-Flex^® service levels and lead-times through Q2 of this year,” said Le Quéré. “The Suwa, Japan production capacity being added in Q4 and the addition of Hangzhou capacity in early 2023 will further strengthen our ability to meet the needs of the bioprocess industry.”

The C-Flex^® production expansion to the Saint-Gobain facility in Suwa, Japan is part of a multi-year manufacturing strategy, increasing Bioprocess Solutions business unit production capacity around the globe, creating redundant manufacturing capabilities across Europe, North America, and Asia to support increasing customer demand.

The Saint-Gobain Suwa facility has been in operation since 1992 and employs approximately 100 employees, providing production capability to multiple businesses within the Saint-Gobain Group.

About Saint-Gobain Life Sciences

Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical, and pharmaceutical customers around the world.

Saint-Gobain Life Sciences is part of Saint-Gobain Group, a worldwide leader in light and sustainable construction, which designs, manufactures, and distributes materials and services for the construction and industrial markets.

€44.2 billion in sales in 2021

166,000 employees, located in 75 countries

Committed to achieving Carbon Neutrality by 2050

For more details on Saint-Gobain, visit: http://www.saint-gobain.com and follow us on Twitter @saintgobain.

And visit: https://www.biopharm.saint-gobain.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005135/en/

Contacts

Katy Oroszi

Saint-Gobain Life Sciences

Marketing Communications Manager

Katy.oroszi@saint-gobain.com